Wall Street Zen Upgrades OptimizeRx (NASDAQ:OPRX) to Strong-Buy

OptimizeRx (NASDAQ:OPRX) was upgraded by research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Sunday.

Other equities analysts have also recently issued research reports about the stock. Zacks Research raised shares of OptimizeRx from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 14th. UBS Group set a $23.00 price target on OptimizeRx in a report on Friday, October 10th. JMP Securities boosted their price objective on OptimizeRx from $20.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday, October 10th. Citizens Jmp raised their target price on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of OptimizeRx in a research note on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.88.

OptimizeRx Trading Down 1.3%

NASDAQ OPRX opened at $13.18 on Friday. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.20. The business has a fifty day simple moving average of $16.95 and a 200 day simple moving average of $15.97. OptimizeRx has a 12 month low of $3.99 and a 12 month high of $22.25. The firm has a market capitalization of $245.69 million, a P/E ratio of 35.08 and a beta of 1.10.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Thursday, November 6th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.03 by $0.17. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%. The company had revenue of $26.07 million during the quarter, compared to the consensus estimate of $23.83 million. On average, analysts predict that OptimizeRx will post -0.33 EPS for the current fiscal year.

Insider Transactions at OptimizeRx

In other OptimizeRx news, CEO Stephen L. Silvestro sold 1,620 shares of the business’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $18.75, for a total value of $30,375.00. Following the sale, the chief executive officer directly owned 188,916 shares in the company, valued at $3,542,175. The trade was a 0.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 5.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On OptimizeRx

Large investors have recently added to or reduced their stakes in the company. American Century Companies Inc. lifted its holdings in OptimizeRx by 9.6% during the first quarter. American Century Companies Inc. now owns 15,783 shares of the company’s stock valued at $137,000 after purchasing an additional 1,387 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of OptimizeRx by 600.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after purchasing an additional 1,818 shares during the period. Parkman Healthcare Partners LLC lifted its stake in shares of OptimizeRx by 0.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock valued at $10,447,000 after buying an additional 2,188 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after buying an additional 2,215 shares during the period. Finally, Rhumbline Advisers grew its stake in OptimizeRx by 10.5% in the 1st quarter. Rhumbline Advisers now owns 27,785 shares of the company’s stock valued at $241,000 after buying an additional 2,636 shares in the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.